Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | STAT6 | P42226 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25808148 | 0.92 | SLC29A1 (0.51) | SLC29A1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL22577529 | 0.82 | TYMP (0.56) | SLC29A1ADORA2AADORA2BADORA1 | |
| SCHEMBL25816604 | 0.82 | SLC29A1 (0.39) | SLC29A1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL14156814 | 0.80 | LMNA (0.48) | SLC29A1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL14156805 | 0.80 | LMNA (0.57) | SLC29A1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL20691367 | 0.79 | SLC29A1 (0.51) | SLC29A1TP53 | |
| SCHEMBL21145007 | 0.77 | SLC29A1 (0.74) | SLC29A1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL14156811 | 0.77 | SLC29A1 (0.48) | SLC29A1ADORA3ADORA1TP53 | |
| SCHEMBL7054035 | 0.76 | SLC29A1 (1.00) | SLC29A1ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL7054042 | 0.76 | SLC29A1 (1.00) | SLC29A1ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
| EP-3727401-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | SLC29A1 252/4885ADORA2A 70/4885ADORA2B 148/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | SLC29A1 231/4885ADORA2A 69/4885ADORA2B 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.